WINGS

"West Nile Integrated Shield Project: Epidemiology, Diagnosis and Prevention of West Nile Virus in Europe"

 Coordinatore FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V 

 Organization address address: Hansastrasse 27C
city: MUENCHEN
postcode: 80686

contact info
Titolo: Ms.
Nome: Andrea
Cognome: Zeumann
Email: send email
Telefono: 498912000000
Fax: 49891200000000

 Nazionalità Coordinatore Germany [DE]
 Totale costo 3˙922˙214 €
 EC contributo 2˙938˙497 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2010-single-stage
 Funding Scheme CP-FP
 Anno di inizio 2011
 Periodo (anno-mese-giorno) 2011-02-01   -   2014-02-28

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V

 Organization address address: Hansastrasse 27C
city: MUENCHEN
postcode: 80686

contact info
Titolo: Ms.
Nome: Andrea
Cognome: Zeumann
Email: send email
Telefono: 498912000000
Fax: 49891200000000

DE (MUENCHEN) coordinator 427˙720.10
2    STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER

 Organization address address: LANGE KLEIWEG 161
city: RIJSWIJK ZH
postcode: 2288 GJ

contact info
Titolo: Dr.
Nome: Ernst
Cognome: Verschoor
Email: send email
Telefono: +31 015 284 2592
Fax: +31 015 284 2601

NL (RIJSWIJK ZH) participant 508˙135.50
3    NOVAVAX AB

 Organization address address: KUNGSGATAN 109
city: UPPSALA
postcode: 753 18

contact info
Titolo: Dr.
Nome: Gerd
Cognome: Rundström
Email: send email
Telefono: +46 18 57 24 06
Fax: +46 18 57 24 01

SE (UPPSALA) participant 474˙660.00
4    UNIVERSITEIT GENT

 Organization address address: SINT PIETERSNIEUWSTRAAT 25
city: GENT
postcode: 9000

contact info
Titolo: Ms.
Nome: Saskia
Cognome: Vanden Broeck
Email: send email
Telefono: +32 9 264 3124
Fax: +32 9 264 3583

BE (GENT) participant 341˙144.40
5    UNIVERSITA DEGLI STUDI DI PADOVA

 Organization address address: VIA 8 FEBBRAIO 2
city: PADOVA
postcode: 35122

contact info
Titolo: Prof.
Nome: Giorgio
Cognome: Palù
Email: send email
Telefono: +39 049 8272350
Fax: +39 049 8272355

IT (PADOVA) participant 330˙434.00
6    THE WASHINGTON UNIVERSITY CORPORATION

 Organization address address: Office of Sponsored Research Services -One Brookings Drive
city: ST LOUIS
postcode: MO 63130-4899

contact info
Nome: Connie
Cognome: Motoki
Email: send email
Telefono: +1 314 935 9443
Fax: +1 314 935 5862

US (ST LOUIS) participant 308˙613.00
7    UNIVERSITAET LEIPZIG

 Organization address address: RITTERSTRASSE 26
city: LEIPZIG
postcode: 4109

contact info
Titolo: Mr.
Nome: Gerhard
Cognome: Fuchs
Email: send email
Telefono: +49 341 9735012
Fax: +49 341 9735009

DE (LEIPZIG) participant 297˙950.00
8    GENETIC IMMUNITY KUTATASI FEJLESZTESI ES SZOLGALTATO KFT

 Organization address address: BERLINI U 47-49
city: BUDAPEST
postcode: 1045

contact info
Titolo: Ms.
Nome: Katalin
Cognome: Hermann
Email: send email
Telefono: 3612720364
Fax: 3612720365

HU (BUDAPEST) participant 151˙200.00
9    UNIVERSITAET ZUERICH

 Organization address address: Raemistrasse 71
city: ZURICH
postcode: 8006

contact info
Titolo: Prof.
Nome: Kurt
Cognome: Bürki
Email: send email
Telefono: 41446355450
Fax: 41446356875

CH (ZURICH) participant 98˙640.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

proteins    wnv    prevention    immunisation    world    wings    borne    america    vector    actions    virus    before    delivered    addition    infections    spread    endemic    promising    human    disease    data    strains    vaccine    inside    body    threatening    candidate    potent    diseases    outbreaks    humans    efforts    prevent    tools    protein    north    taken    significant    recombinant    scientific    dna    fight    protective    viral    nile    antigen    west    infection    years    either    vaccines   

 Obiettivo del progetto (Objective)

'The world is facing a variety of viral infections of high pathogenic potential. These are either novel or formerly only endemic in specific areas of the world. It is intrinsic to such emerging diseases that actions to prevent and fight them must be taken while the number of infections is still relatively low and geographically restricted. Therefore, research efforts are required well before large outbreaks occur. In addition, effective surveillance networks for a given emerging disease must be established in time. Only with tools for treatment and control (such as vaccines) it will be possible to avoid major uncontrolled outbreaks. This proposal aims at the development of these tools for the control and prevention of one of the most threatening vector-borne emerging diseases, West Nile Fever, caused by West Nile Virus (WNV), which has recently spread through North America. Although the viral strains are similar in America and Europe, different conditions for a WNV epidemic have to be taken into account, like insect vectors, reservoir hosts (birds) and their endemic virus populations plus specialities of European climate and geography. To achieve the goals of the call and to make a significant impact in the enhancement of Europe´s preparedness to WNV, the consortium has defined three major scientific and technical objectives. Firstly, to develop a diagnostic system for WNV-infections, which has no cross-reaction with other common flavivirus infections. Secondly, to develop a vaccine for humans and last but not least to establish a scientific network to collect, investigate and standardize biological data associated with WNV records using standardized methods. Several European Institutes supported by US scientist experienced with the North American outbreak will be collaborating to fight the disease from a European perspective.'

Introduzione (Teaser)

In recent years, outbreaks of West Nile Virus (WNV), a mosquito-transmitted pathogen, are increasing in number and geographic distribution in Europe. Actions to prevent emerging diseases must be taken before large outbreaks occur.

Descrizione progetto (Article)

Currently, there is no vaccine available to protect humans against WNV infection. The EU-funded http://www.west-nile-shield-project.eu (WINGS) proposal aimed to develop tools for the control and prevention of one of the most threatening vector-borne emerging diseases. The goal of the WINGS investigators was to identify the most potent antigen (target) and develop immunisation strategies against rapidly adaptable, newly emerging WNV strains.

During the three years of the project, the scientific team analysed several proteins that form the viral envelope of the European strain and cloned the most relevant genes for vaccine development and biomarker assays. They tested protein vaccine/adjuvant combinations using animal models and selected the most potent ones.

Another approach to immunisation against WNV utilised DNA-based vaccination. This approach relies on the ability of the organism to propagate the vaccine inside the body in response to the immunisation. The scientists used nanoparticles to enhance the delivery of the DNA and to prolong the half-life of the vaccine antigen inside the human body.

The consortium successfully developed several candidate vaccines consisting of either recombinant proteins or DNA, or a mixture of both. The most promising vaccine candidate showed long-lasting complete protection in mice and non-human primates. The vaccine was well tolerated, protective against different circulating European WNV strains, and displayed high immunogenicity and protective capacity. In addition, as the most promising candidate is based on a recombinant protein expressed in bacteria, the vaccine can be produced in high yields.

In addition, researchers developed several tools for the specific diagnosis of WNV infection. A novel method enables the detection and isolation of WNV from urine samples. This is a significant advantage over existing protocols because of its higher sensitivity in comparison to blood sample testing.

In sum, the WINGS project delivered several novel technologies and tools to specifically detect and efficiently counteract the WNV threat. These efforts delivered valuable data about WNV biology, and prepare Europe for its potential spread.

Altri progetti dello stesso programma (FP7-HEALTH)

RN4CAST (2009)

Nurse Forecasting: Human Resources Planning in Nursing

Read More  

EDUFLUVAC (2013)

Combinatorial immunization strategy to educate the immune system towards cross recognition and coverage against antigenic drift in seasonal influenza virus exposure

Read More  

GENICA (2008)

Genomic Instability in Cancer and Precancer

Read More